Zolmitriptan inhalation - Acorda Therapeutics

Drug Profile

Zolmitriptan inhalation - Acorda Therapeutics

Alternative Names: CVT 427; Zolmitriptan inhalation powder

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 27 Apr 2017 Acorda Therapeutics terminates before initiation a phase II trial for Migraine
  • 01 Dec 2016 Acorda Therapeutics completes a phase I trial in Migraine in USA (Inhalation) (NCT02905227)
  • 01 Sep 2016 Acorda Therapeutics initiates a phase I trial for Migraine in USA (Inhalation) (NCT02905227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top